Big Pharma Approvals — April 28, 2026

FDA NME approval for ANIFROLIMAB-FNIA grants AstraZeneca AB a high-value first-in-class asset with potential 5-year exclusivity. Rated bullish at 8/10 strength and 8/10 materiality, highlighting robust commercial upside.

Label expansion approval for PEMBROLIZUMAB bolsters Merck Sharp Dohme's KEYTRUDA franchise with added indications. Bullish signal at 5/10 strength and 5/10 materiality amid ongoing portfolio momentum.

FDA label expansion for PERTUZUMAB (PERJETA) supports Genentech's oncology presence with expanded use. Rated bullish at 5/10 strength and 5/10 materiality, signaling sustained execution.

AstraZeneca AB's ANIFROLIMAB-FNIA (SAPHNELO) NME approval unlocks new market entry with first-in-class positioning

Merck Sharp Dohme's PEMBROLIZUMAB (KEYTRUDA QLEX) expansion broadens addressable patient population for KEYTRUDA

Genentech's PERTUZUMAB (PERJETA) label expansion enhances PERJETA's clinical utility

Three bullish Other approvals across AstraZeneca AB, Merck Sharp Dohme, and Genentech demonstrate consistent FDA success for established players.

{"entity"=>"ANIFROLIMAB-FNIA (ASTRAZENECA AB)", "reason"=>"Highest-conviction NME with undisclosed commercial metrics requires validation", "trigger"=>"initial launch sales and market uptake data"}

{"entity"=>"PEMBROLIZUMAB (MERCK SHARP DOHME)", "reason"=>"Label expansion impact on KEYTRUDA QLEX sales trajectory", "trigger"=>"Q2 2026 sales readout"}

{"entity"=>"PERTUZUMAB (GENENTECH)", "reason"=>"Label expansion effects on PERJETA positioning", "trigger"=>"guideline inclusion updates"}